Lakefront Biotherapeutics (GLPGF) Inventory Average (2015 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Inventory Average for 9 consecutive years, with $23.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Inventory Average fell 50.75% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $23.4 million, a 50.75% decrease from a year earlier, with the FY2025 full-year figure at $40.4 million, down 40.13% from the prior year.
• Inventory Average was $23.4 million for Q1 2026 at Lakefront Biotherapeutics, down from $26.5 million in the prior quarter.
• Over five years, Inventory Average peaked at $27.0 billion in Q1 2023 and troughed at $23.4 million in Q1 2026.
• A 5-year average of $3.9 billion and a median of $55.5 million in 2024 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average surged 129.51% in 2023 and plunged 99.69% in 2024, its largest moves.
• Over 5 years, Inventory Average stood at $11.8 billion in 2022, then plunged by 99.41% to $70.1 million in 2023, then dropped by 9.58% to $63.4 million in 2024, then sank by 58.16% to $26.5 million in 2025, then dropped by 11.53% to $23.4 million in 2026.
• The last three Inventory Average figures came in at $23.4 million (Q1 2026), $26.5 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.